Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children

Journal of Infectious Diseases

Volumn 185, Issue 10, 2002, Pages 1409-1416

  Saitoh, Akihiko ^a   Hsia, Karen ^a   Fenton, Terence ^d   Powell, Christine A ^d   Christopherson, Cindy ^c   Fletcher, Courtney V ^e   Starr, Stuart E ^f   Spector, Stephen A ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ARTICLE; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; DISEASE MARKER; DRUG RESPONSE; FEMALE; HALF LIFE TIME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; NELFINAVIR; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 0037094107     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/340614     Document Type: Article

References (35)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1
5. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
6. +lymphocyte count improves assessment of antiretroviral therapeutic response
7. +lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
8. HIV viral load markers in clinical practice
9. +lymphocytes as prognostic markers of HIV-1 infection
10. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial
11. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
12. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
13. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
14. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
15. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
16. +T lymphocytes in infected children
17. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
18. HIV-1 dynamics in children
19. Immune repopulation after HAART in previously untreated HIV-1-infected children
20. +T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients
21. +T lymphocytes in children on highly active antiretroviral therapy
22. +T cells during primary HIV-1 infection
23. Quantification of HIV-1 viral load in lymphoid and blood cells: Assessment during four-drug combination therapy
24. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons
25. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy
26. Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA
27. Decay of cell-associated HIV- 1 DNA correlates with residual replication in patients treated during acute HIV-1 infection
28. PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells
29. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy
30. 6/l CD4 cells treated with highly active antiretroviral therapy
31. Decay characteristics of HIV-1-infected compartments during combination therapy
32. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment
33. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children
34. Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy
35. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients